SECsense Logo

Tiziana Life Sciences LTD: 2025 Report on Nasal Anti-CD3 Antibody Findings

$TLSA
Form 6-K
Filed on: 2025-01-10
Source
Tiziana Life Sciences LTD: 2025 Report on Nasal Anti-CD3 Antibody Findings

The key information extracted from the provided section of the financial report (Form 6-K) is as follows:

  1. Company Information:
  • Name: Tiziana Life Sciences LTD
  • Commission File Number: 001-38723
  • Address:
    • 9th Floor
    • 107 Cheapside
    • London, EC2V 6DN
  1. Report Details:
  • Type of Report: Report of Foreign Private Issuer
  • Filing Date: January 10, 2025
  • Rule Reference: Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
  1. Announcement:
  • The company announced findings related to its nasal anti-CD3 monoclonal antibody, which shows prolonged benefits in sustaining tissue homeostasis and mitigating side effects associated with discontinuation of GLP-1 agonists. This suggests a potential solution to tolerability issues linked to long-term GLP-1 drug use.
  1. Exhibit Information:
  • The findings are detailed in an attached press release (Exhibit 99.1) which is included as part of the report. This document is not deemed "filed" under the Securities Exchange Act of 1934.
  1. Signature:
  • The report was signed by Keeren Shah, the Chief Financial Officer of Tiziana Life Sciences LTD.
  1. Regulatory Notes:
  • The information contained in Exhibit 99.1 is furnished and will not be considered filed for liability purposes under Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in other filings under the Securities Act of 1933 or the Securities Exchange Act of 1934.

This summary provides a concise overview of the relevant details from the report, highlighting key company information, the essence of the announcement, and regulatory considerations.